Clinical Trial Detail

NCT ID NCT02576990
Title Study of Pembrolizumab (MK-3475) in Participants With Advanced Primary Mediastinal Large B-cell Lymphoma (MK-3475-170/KEYNOTE-170)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

diffuse large B-cell lymphoma

Therapies

Pembrolizumab

Age Groups: adult

No variant requirements are available.